Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0292087 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Udit Nindra und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Next generation sequencing (NGS) is increasingly used in standard clinical practice to identify patients with potentially actionable mutations. Stratification of NGS mutation tiers is currently based on the European Society of Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT[E]) Tier I–V & X. Allele frequency is also increasingly recognised as an important prognostic tool in advanced cancer. The aim of this study was to determine the genomic mutations in metastatic colorectal cancer (CRC) in an Australian multicultural population and their influence on survival outcomes.
Methods
Next generation sequencing with the 50-gene panel Oncomine Precision Assay ™ was used on 180 CRC tissue samples obtained across six Sydney hospitals between June 2021 and March 2022.
Results
From 180 samples, 147 (82%) had at least one gene mutation identified with 68 (38%) having two or more concurrent mutations. Tier I variants included RAS wild-type [EI] in 73 (41%) and BRAF V600E [EIA] in 27 (15%). Non-tier I variants include 2 (1%) ERBB2 amplification [EIIB], 26 (15%) PIK3CA hotspot mutations [EIIIA] and 9 (5%) MET focal amplifications [EIIIA]. NGS testing revealed an additional 22% of cases with Tier II & III mutations. 43% of patients also presented with potentially actionable Tier III & IV mutations. Patients with concurrent TP53 and RAS mutations had significantly reduced overall survival (6.1 months versus 21.1 months, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Medical Oncology, Liverpool Hospital, Liverpool, New South Wales, Australia.
- Department of Medical Oncology, Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, New South Wales, Australia.
- Department of Medical Oncology, Bankstown-Lidcombe Hospital, Bankstown, New South Wales, Australia.
- Ingham Institute for Applied Medical Research, Liverpool, Australia.
- School of Medicine, Western Sydney University, Sydney, Australia.
- Department of Anatomical Pathology, Liverpool Hospital, Liverpool, Sydney, Australia.
ORCID-Profile: Udit Nindra, Stephanie Hui-Su Lim
Zitieren
APA
Nindra, U., Pal, A., Lea, V., Lim, S. H., Wilkinson, K., Asghari, R., Roberts, T. L., Becker, T. M., Farzin, M., Rutland, T., Lee, M., MacKenzie, S., Ng, W., Wang, B., Lee, C. S., & Chua, W. (2023). Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population. PLOS ONE. https://doi.org/10.1371/journal.pone.0292087
Vancouver
Nindra U, Pal A, Lea V, Lim SH, Wilkinson K, Asghari R, et al. Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population. PLOS ONE. 2023. doi:10.1371/journal.pone.0292087
BibTeX
@article{Nindra2023,
author = {Nindra, Udit and Pal, Abhijit and Lea, Vivienne and Lim, Stephanie Hui-Su and Wilkinson, Kate and Asghari, Ray and Roberts, Tara L and Becker, Therese M and Farzin, Mahtab and Rutland, Tristan and Lee, Mark and MacKenzie, Scott and Ng, Weng and Wang, Bin and Lee, C Soon and Chua, Wei},
title = {Multigene panel next generation sequencing in metastatic colorectal cancer in an Australian population},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0292087}
}
EUVIMED